Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Changes in tryptophan metabolite levels in the pathogenesis of inflammatory bowel diseases

About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Kazan State Medical University, Kazan, Russia

3 Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Kazan, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Correspondence should be addressed: Vladimir A. Sorokin
Ostrovityanova, 1, Moscow, 117997, Russia; ur.liam@a_v_nikoros

About paper

Funding: the article is based on the results of implementation of Grant Agreement No. 075-15-2022-310 of April 20, 2022, which provides for federal budget subsidies as state support for the establishment and development of world-class scientific centers conducting research and development in priority areas of scientific and technological advancement.

Author contribution: Sorokin VA — data collection and analysis, literature analysis, manuscript preparation; Apollonova SA — physico-chemical and laboratory analyses, data analysis; Abdulkhakov SR — study planning, data analysis; Shakirova GF — data collection and analysis, literature analysis; Odintsova AH — data collection, patient examination and supervision; Abdulkhakov RA — study planning, data interpretation; Rumyantsev SA — study planning, general guidance; Shestopalov AV — study planning, data analysis, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Pirogov Russian National Research Medical University (Minutes No. 186 of June 26, 2019). All patients signed a voluntary informed consent to participate in the study.

Received: 2026-09-18 Accepted: 2026-11-02 Published online: 2026-11-15
|

Inflammatory bowel diseases (IBD) are characterized by progressive damage to the intestinal wall and a relapsing course. The pathogenesis of IBD, including the role of microbial tryptophan metabolism, remains incompletely understood. This single-center, cross-sectional study aimed to compare fecal and serum concentrations of tryptophan-derived indole metabolites between patients with IBD and healthy controls. The study included 29 patients with acute IBD and 36 healthy volunteers. Stool and venous blood samples were analyzed by high-performance liquid chromatography coupled with tandem mass spectrometry. In feces, the indole concentration decreased to 3.851 vs. 287.12 nmol/g (p < 0.0001); indole-3-butyrate grew to 0.881 vs. 0.02 (p < 0.0001); indole-3-acetate increased to 23.202 vs. 8.962 (p = 0.0090). In serum, tryptamine concentrations decreased to 0.120 vs. 0.775 nmol/L (p < 0.0001); serotonin dropped to 528.86 vs. 721.592 (p = 0.0051); and indole-3-butyrate concentrations increased to 4.66 vs. 3.564 (p = 0.0166). Among men with IBD, serum tryptamine dropped to 0.117 vs. 0.612 nmol/L (p < 0.0001), while indole-3butyrate grew to 6.267 vs. 3.223 (p = 0.0004). Among women with IBD, tryptamine decreased to 0.115 vs. 0.805 nmol/L (p < 0.0001), and serotonin concentrations were 42% lower (p = 0.0065). In men with IBD, serum indole-3-butyrate concentrations were 1.8 times higher than in women with IBD. Thus, in the presence of IBD, both microbial and systemic tryptophan metabolism are altered. Reduced indole levels may reflect inhibited microbial tryptophanase activity, whereas increased concentrations of individual indoles may indicate a compensatory rearrangement of microbial tryptophan metabolism. Sex-related differences were observed in the serotonin and indole pathways, which may modulate tolerogenic immune regulation through the aryl hydrocarbon receptor (AHR) and thereby influence intestinal inflammation.

Keywords: inflammatory bowel diseases, tryptophan metabolites, indole derivatives, intestinal microbiota, aryl hydrocarbon receptor

КОММЕНТАРИИ (0)